In our cohort of 905 breast cancer patients undergoing neoadjuvant chemotherapy, we found the intense association between HER2-low expression and HR-positive status (P < 0.001), and confirmed the possible role for ER in HER2-low expression biology (20, 21). The gene discussed is ESR1; the disease is breast carcinoma.